This is a medical procedure used to get stem cells from your bone marrow into your bloodstream. These stem cells are then collected for use in treatments like stem cell transplantation. Doctors might use special medicines to help the stem cells move out of the bone marrow.
Every report comes from a Lived member, sent anonymously.
No reports yet
Add what worked for you with the search bar below
Stem cell mobilization is the first stage of collecting blood-forming stem cells for a stem cell transplant. These cells live mainly in the bone marrow, the spongy tissue inside bones, where they produce red blood cells, white blood cells and platelets. Only a small number normally circulate in the blood. Mobilization uses medicine to move many more of them out of the marrow and into the bloodstream, where a machine can collect them in a process called apheresis. Most people who go through mobilization are preparing for an autologous transplant, meaning they will receive their own cells back. This is common in multiple myeloma and lymphoma. The cells are collected and frozen, the person then receives high-dose chemotherapy that destroys the marrow, and the stored cells are returned to rebuild it. Healthy people donating stem cells to a relative or to an unrelated patient also go through mobilization before their donation. Most stem cells used in transplants now come from the blood rather than from a marrow harvest, in which cells are drawn out of the hip bone under general anesthesia. Collecting from the blood avoids repeated needle punctures into bone, and these cells tend to restore blood counts faster after transplant. The transplant team decides which source suits the person who will receive the cells.
The core of mobilization is a course of injections under the skin. Most plans use filgrastim, a lab-made version of granulocyte colony-stimulating factor (G-CSF), a natural hormone that drives the marrow to make white blood cells and releases stem cells into the blood. Neupogen is the original brand, and biosimilar versions such as Zarxio work the same way. The injections are given daily for at least four days before the first collection and continue each day until collection is finished. Blood counts are checked along the way. People with myeloma or lymphoma may be offered one of several approaches. Growth factor alone is the simplest. Chemotherapy followed by growth factor can reduce the amount of cancer and increase the number of cells collected, but it adds chemotherapy side effects, including a stretch of low blood counts. A third option adds a medicine that blocks the signal holding stem cells in the marrow: plerixafor (Mozobil and generic versions) for myeloma or non-Hodgkin lymphoma, or motixafortide (Aphexda) for myeloma. It is given as an injection several hours before each collection and is often used for people expected to have trouble collecting enough cells, such as those who have had a lot of earlier treatment. The team also checks whether the arm veins are large enough for collection. If they are not, a central venous catheter, a flexible tube placed into a large vein, is put in beforehand. Plerixafor and motixafortide can harm a developing baby, so anyone who is pregnant or could become pregnant should discuss this and contraception with the team. People with sickle cell disease should make sure the team knows, for reasons explained under risks.
Collection takes place in an apheresis unit. Blood is drawn through a needle in one arm or through the catheter, passes through a machine that spins out the stem cells, and the rest of the blood is returned. Each session takes about four to six hours, and the person stays awake throughout. The goal is a set number of stem cells, counted by a marker on their surface called CD34. A common minimum for one autologous transplant is about 2 million CD34 cells for each kilogram of the recipient's body weight. If one day's collection falls short, the injections continue and another session follows the next day. Some people finish in a single session, while others need several consecutive days. During collection, some people feel lightheaded or chilled, or notice numbness around the lips and cramping in the hands. These are common, so mention them to the staff as soon as they start.
The collected cells are processed and frozen until the transplant. Most people go home after each session. Growth-factor side effects, chiefly bone pain along with headache, fatigue, nausea, trouble sleeping and flu-like aches, usually fade within two to three days of the last injection. Acetaminophen (Tylenol) is commonly used for the aches; let the care team know if symptoms get worse. People who also received plerixafor or motixafortide may have nausea, diarrhea, dizziness, or pain and redness at the injection site. If a catheter is in place, the team explains how to keep it clean and covered. For people mobilized with chemotherapy, low white blood cell counts make infections more dangerous for a period afterward. A fever of 100.5 F (38 C) or higher, shaking chills, or redness and swelling where the catheter enters the skin calls for contacting the care team right away.
Most side effects of mobilization are temporary and come from the medicines rather than the collection itself. Bone pain is the most common; about 3 in 10 patients reported it while taking filgrastim for mobilization in the main study behind its approval. A rare but serious effect of filgrastim and plerixafor is enlargement or rupture of the spleen, an organ under the ribs on the upper left side of the abdomen. Pain in the upper left abdomen or in the shoulder during the injection days needs a call to the care team right away, and severe abdominal pain with fainting needs emergency care. Serious allergic reactions are uncommon; plerixafor and motixafortide are given where staff can treat one, and motixafortide is given after anti-allergy premedicines. Filgrastim can trigger a severe, sometimes fatal sickle cell crisis in people with sickle cell disease, which shapes whether and how they are mobilized. When plerixafor or motixafortide is combined with filgrastim, some cancer cells can be released from the marrow and collected with the stem cells. The effect of returning them during transplant is not known, and these medicines are not used for people with leukemia. Not everyone collects enough cells on the first attempt. Poor collection is more likely after extensive earlier treatment and can delay transplant. Adding plerixafor to the growth factor makes reaching the target more likely. Healthy donors share the short-term growth-factor side effects; filgrastim is widely used for donors although the US Food and Drug Administration has not approved it for this use, and rare bleeding into the lungs, which can show up as coughing up blood, has been reported in donors.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share your experience with Stem Cell Mobilization, what to expect, or ask the community a question.